Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria (Q36681333)

15 August 2017

1 reference

title

Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria (English)

1 reference

15 August 2017

0 references

Plasmodium falciparum

0 references

lumefantrine

1 reference

based on heuristic

inferred from title

artemether/lumefantrine

1 reference

3

Alexis Nzila

1 reference

15 August 2017

2

Leah Mwai

1 reference

15 August 2017

Gilbert Kokwaro

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 January 2007

1 reference

Expert Opinion on Pharmacotherapy

15 August 2017

published in

1 reference

15 August 2017

volume

8

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

75-94

1 reference

Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Pharmacokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Clinical pharmacokinetics and pharmacodynamics and pharmacodynamics of artemether-lumefantrine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Artemether-lumefantrine for uncomplicated malaria: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

The comparative efficacy and tolerability of CGP 56697 (artemether lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Death and blindness due to overdose of quinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Quinine overdose: review of toxicity and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Complications of quinine poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Neurotoxicity in animals due to arteether and artemether

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Interaction trial between artemether-lumefantrine (Riamet) and quinine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Cardiac effects of co-artemether (artemether/lumefantrine) and mefloquine given alone or in combination to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

The safety of antimalarial drugs in pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Artemisinin antimalarials in pregnancy: a prospective treatment study of 539 episodes of multidrug-resistant Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Role of arteether in the treatment of malaria and plans for further development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Inhibition of hERG K currents by antimalarial drugs in stably transfected HEK293 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Arteether-induced brain injury in Macaca mulatta. I. The precerebellar nuclei: the lateral reticular nuclei, paramedian reticular nuclei, and perihypoglossal nuclei.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Effects of arteether on an auditory radial-arm maze task in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Neurotoxicity of artemisinin analogs in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Enhanced in vitro neurotoxicity of artemisinin derivatives in the presence of haemin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Artemisinin derivatives: toxic for laboratory animals, safe for humans?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

A trial of artemether or quinine in children with cerebral malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Ataxia and slurred speech after artesunate treatment for falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Toxic brainstem encephalopathy after artemisinin treatment for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Artemether-lumefantrine for the treatment of multidrug-resistant falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

No hearing loss associated with the use of artemether-lumefantrine to treat experimental human malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Antimalarial drug resistance and combination chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Current perspectives on the mechanism of action of artemisinins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

A meta-analysis of the association between adherence to drug therapy and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

How do patients use antimalarial drugs? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Adherence to a combination of artemether and lumefantrine (Coartem) in Kajo Keji, southern Sudan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Feasibility and acceptability of the use of artemether‐lumefantrine in the home management of uncomplicated malaria in children 6–59 months old in Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Efficacy of therapeutic combinations with artemisinin derivatives in the treatment of non complicated malaria in Burundi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Reduction of malaria transmission to Anopheles mosquitoes with a six-dose regimen of co-artemether

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

The difference between effectiveness and efficacy of antimalarial drugs in Kenya

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Amodiaquine alone, amodiaquine sulfadoxine-pyrimethamine, amodiaquine artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

In-vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Brands, costs and registration status of antimalarial drugs in the Kenyan retail sector

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Cost effectiveness analysis of strategies to combat malaria in developing countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Artemisinin-based combination therapy reduces expenditure on malaria treatment in KwaZulu Natal, South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

Excretion of mefloquine in human breast milk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/14656566.8.1.75

21 January 2018

Identifiers

DOI

10.1517/14656566.8.1.75

1 reference

15 August 2017

1 reference